Price range: 230 € through 780 €

Retatrutide (LY3437943), also known as RT, is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. This configuration contains 10 individual vials specified at 50 mg per vial, providing 500 mg of nominal total peptide content per kit. Retatrutide is being investigated in metabolic and cardiometabolic research, including obesity, type 2 diabetes, cardiovascular outcomes, metabolic liver disease, obstructive sleep apnea and obesity-associated conditions. Intended for legitimate research purposes and not currently FDA-approved for general public use.